{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:43:45Z","timestamp":1791020625389,"version":"4.1.0"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T00:00:00Z","timestamp":1289347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:p>\n                    (\n                    <jats:italic>Headache<\/jats:italic>\n                    2011;51:73\u201084)\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective.\u2014<\/jats:bold>\n                    To evaluate the long\u2010term tolerability of telcagepant for acute treatment of intermittent migraine attacks.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Background.\u2014<\/jats:bold>\n                    Telcagepant is a calcitonin gene\u2010related peptide (CGRP) receptor antagonist being investigated for the acute treatment of migraine.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.\u2014<\/jats:bold>\n                    Migraine patients were randomized 2:1 to double\u2010blind treatment with telcagepant 280\/300\u2003mg or rizatriptan 10\u2003mg for an acute mild, moderate, or severe migraine. Patients could administer a second dose within 2\u201024 hours for nonresponse or migraine recurrence. Patients could treat up to 8 attacks per month for up to 18 months. Safety assessments included spontaneous reports of adverse events and collection of vital signs, electrocardiograms, and laboratory assessments. The primary endpoint was the percentage of patients with \u22651 triptan\u2010related adverse events in the 14\u2010day period post dose.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.\u2014<\/jats:bold>\n                    Of 1068 patients randomized, 641 (90%) patients treated \u22651 attack with telcagepant and 313 (88%) treated \u22651 attack with rizatriptan. A total of 19,820 attacks were treated with telcagepant (mean per patient\u2003=\u200331) and 10,981 with rizatriptan (mean per patient\u2003=\u200335). Fewer triptan\u2010related adverse events (difference: \u22126.2%; 95% CI \u221210.4, \u22122.6;\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u2003.001) and drug\u2010related adverse events (difference: \u221215.6%; 95% CI \u221222.2, \u22129.0) were reported for telcagepant vs rizatriptan. The most common adverse events appeared to have generally similar incidence proportions between the treatment groups. Those with an incidence &gt;5% in the telcagepant group were dry mouth (9.7%, rizatriptan\u2003=\u200313.7%), somnolence (9.2%, rizatriptan\u2003=\u200316.6%), dizziness (8.9%, rizatriptan\u2003=\u200310.2%), and nausea (9.0%, rizatriptan\u2003=\u20036.4%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    Telcagepant was generally well tolerated when administered for the acute intermittent treatment of migraine for up to 18 months. The incidences of triptan\u2010related and drug\u2010related adverse events favored telcagepant over rizatriptan.\n                  <\/jats:p>","DOI":"10.1111\/j.1526-4610.2010.01799.x","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T12:10:10Z","timestamp":1289391010000},"page":"73-84","source":"Crossref","is-referenced-by-count":78,"title":["Long\u2010Term Tolerability of Telcagepant for Acute Treatment of Migraine in a Randomized Trial"],"prefix":"10.1111","volume":"51","author":[{"given":"Kathryn M.","family":"Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena K.","family":"Aurora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Loeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Giezek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Massaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams\u2010Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony W.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,10]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06711-3"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2007.10.005"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.11.9.1179"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565180-00002"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030505"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000286940.29755.61"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61626-8"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181b87942"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410370878"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1586\/ern.09.47"},{"issue":"1","key":"e_1_2_7_12_2","first-page":"9","article-title":"The International Classification of Headache Disorders: 2nd edition","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2001.01156.x"},{"key":"e_1_2_7_14_2","first-page":"54","article-title":"A clinical study demonstrates no potential for recreational abuse of telcagepant","volume":"50","author":"Blanchard R","year":"2010","journal-title":"Headache"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04078.x"},{"key":"e_1_2_7_16_2","unstructured":"Merck Sharp & Dohme Corp.Merck Announces First\u2010Quarter 2009 Financial Results [Company Press Release April 21 2009]. Merck Web site.http:\/\/www.merck.com\/newsroom\/news\u2010release\u2010archive\/financial\/home.html. Accessed October 25 2010."}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2010.01799.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2010.01799.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:38:39Z","timestamp":1762079919000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2010.01799.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,10]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1526-4610.2010.01799.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01799.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,10]]}}}